Nuvation Bio Inc.
NUVB· NYSE· Pharmaceutical Preparations
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- –
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- –
We record prices for the companies we cover; NUVB is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 341,541
- Revenue
- $62.9M
- Free cash flow
- –
- Owner earnings
- –
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- –
- Operating
- -338.7%
- Net
- -325.3%
- Free cash flow
- –
- Owner earnings
- –
- Stock pay
- 57.1%
Returns
- ROIC, FY2025
- –
- ROIC, 5 yr avg
- –
- ROE, FY2025
- -66.9%
- ROE, 5 yr avg
- -45.9%
Growth (CAGR)
- Revenue, 3 yr
- –
- Revenue, 5 yr
- –
- Diluted EPS, 3 yr
- –
- Diluted EPS, 5 yr
- –
- Free cash flow, 3 yr
- –
- Free cash flow, 5 yr
- –
Financial health · FY2025
- Cash and investments
- $529.2M
- Total debt
- $52.9M
- Net cash
- $476.3M
- Debt/Equity
- 0.2x
- Debt/FCF
- –
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- –
Financials: ten years from the 10-Ks
Revenue
$62.9M
FY2025
FY2020FY2025
Margins
Gross–Operating-338.7%Net-325.3%
FY2025
FY2020FY2025
Diluted shares
341,541
+72.6% over 5 years, net dilution
FY2020FY2025
Net cash
$476.3M
$476.3M more cash than debt
FY2020FY2025
Every figure, year by year
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| The business | ||||||
| Revenue | – | – | – | $0 | $7.9M | $62.9M |
| Revenue growth | – | – | – | – | – | 699.0% |
| Gross margin | – | – | – | – | 10.1% | – |
| Operating margin | – | – | – | – | -7527.3% | -338.7% |
| Net income | -$41.7M | -$86.8M | -$104.2M | -$75.8M | -$567.9M | -$204.6M |
| Net margin | – | – | – | – | -7213.8% | -325.3% |
| Diluted EPS | – | $-0.44 | $-0.48 | $-0.35 | $-2.11 | $-0.60 |
| Return on invested capital? | – | – | – | – | – | – |
| Cash | ||||||
| Operating cash flow | -$36.5M | -$68.2M | -$96.1M | -$68.0M | -$130.4M | -$173.4M |
| Capital expenditure | – | – | – | – | – | – |
| Free cash flow | – | – | – | – | – | – |
| Stock-based compensation | $2.2M | $9.3M | $16.3M | $19.5M | $32.3M | $35.9M |
| Owner earnings? | – | – | – | – | – | – |
| Free cash flow per share | – | – | – | – | – | – |
| Capital allocation | ||||||
| Dividends paid | – | – | – | – | – | – |
| Share repurchases | – | – | – | – | – | – |
| Diluted shares | – | 197,887 | 216,721 | 218,880 | 268,772 | 341,541 |
| Share count change? | – | – | 9.5% | 1.0% | 22.8% | 27.1% |
| Balance sheet | ||||||
| Cash and equivalents | $29.8M | $132.4M | $101.1M | $42.6M | $35.7M | $164.1M |
| Short-term investments | $186.0M | $633.0M | $559.9M | $568.6M | $467.0M | $365.1M |
| Total debt | – | – | – | – | – | $52.9M |
| Net debt | – | – | – | – | – | -$476.3M |
| Shareholders' equity | $215.1M | $746.0M | $655.1M | $605.1M | $463.8M | $305.7M |
Latest filings
| 2026-08-06 | 8-K | Earnings release |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-05-04 | 8-K | Earnings release |
| 2026-05-04 | 10-Q | Quarterly report |
| 2026-04-10 | DEF 14A | Proxy statement |
| 2026-03-02 | 10-K | Annual report |
| 2026-03-02 | 8-K | Earnings release |
| 2026-01-12 | 8-K | Earnings release |
| 2025-11-03 | 10-Q | Quarterly report |
| 2025-11-03 | 8-K | Earnings release |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
